41510-17-2

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
Ethanone, 1-(5-methoxy-1H-benzimidazol-2-yl)(9CI) serves as a valuable component in pharmaceutical research and drug development due to its potential therapeutic effects. Its unique structure and properties make it a candidate for the treatment of various medical conditions.
Used in the Treatment of Neurological Disorders:
In the medical field, Ethanone, 1-(5-methoxy-1H-benzimidazol-2-yl)(9CI) is considered for its potential application in treating neurological disorders. The exact mechanisms of its action are still under investigation, but its presence in drug development pipelines indicates its promise in this area.
Used in Cancer Therapy:
Ethanone, 1-(5-methoxy-1H-benzimidazol-2-yl)(9CI) also shows potential in cancer therapy. Its role in this context is being explored for its possible contribution to the treatment of various types of cancer, highlighting its versatility as a pharmaceutical agent.
The ongoing research into the biological and pharmacological activities of Ethanone, 1-(5-methoxy-1H-benzimidazol-2-yl)(9CI) will provide further insights into its applications, solidifying its place in the development of novel therapeutic strategies.

Upstream product

• 102-51-2 4-methoxy-1,2-phenylenediamine 
• 37523-81-2 C₁₀H₁₂N₂O₂ 
• 37523-81-2 5-Methoxy-2-(1-hydroxy-aethyl)-benzimidazol 

Downstream Products

• 1021915-01-4 C₁₈H₁₅BrN₂O₃ 
• 1021915-02-5 C₁₈H₁₅BrN₂O₃ 

Relevant academic research and scientific papers

Compositions containing five-membered unsaturated heterocyclic structure of the α, β unsaturated ketone compound and its preparation method and application

The invention provides alpha, beta unsaturated ketone compounds containing benzo five-membered unsaturated heterocycle structures as well as a preparation method and an application and use of the compounds. The alpha, beta unsaturated ketone compounds containing the benzo five-membered unsaturated heterocycle structures have the structure of a formula (I). In addition, the invention further provides a method for preparing the compounds and a pharmaceutical composition containing the components as active components. In vitro activity tests show that the compounds provided by the invention show a remarkable inhibiting effect on tumor cells. Therefore, the invention lays a foundation for lucubrating and developing anti-tumor medicines in the future and meanwhile further provides a new technical means for treating tumor diseases.

Discovery of small molecule benzimidazole antagonists of the chemokine receptor CXCR3

High-throughput screening identified a low molecular weight antagonist of CXCR3 displaying micromolar activity in a membrane filtration-binding assay. Systematic modification of the benzimidazole core and tethered acetophenone moiety established tractable SAR of analogs with improved physicochemical properties and sub-micromolar activity across both human and murine receptors.